Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lisa A Teot, M.D.

Co-Author

This page shows the publications co-authored by Lisa Teot and Torunn Yock.
Connection Strength

0.182
  1. Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer Med. 2021 02; 10(3):857-866.
    View in: PubMed
    Score: 0.057
  2. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2019 01 15; 125(2):290-297.
    View in: PubMed
    Score: 0.049
  3. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2018 09 20; 36(27):2770-2777.
    View in: PubMed
    Score: 0.048
  4. Orbital sarcoma with metastases at diagnosis: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2010 Jul 01; 54(7):1045-7.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.